MCID: PRM293
MIFTS: 43

Primary Mediastinal B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Mediastinal B-Cell Lymphoma

MalaCards integrated aliases for Primary Mediastinal B-Cell Lymphoma:

Name: Primary Mediastinal B-Cell Lymphoma 12 15
Mediastinal Diffuse Large-Cell Lymphoma with Sclerosis 12
Primary Mediastinal Clear Cell Lymphoma of B-Cell Type 12
Large Cell Lymphoma of the Mediastinum 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080210
ICD10 32 C85.2

Summaries for Primary Mediastinal B-Cell Lymphoma

Disease Ontology : 12 A diffuse large B-cell lymphoma that is is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis.

MalaCards based summary : Primary Mediastinal B-Cell Lymphoma, also known as mediastinal diffuse large-cell lymphoma with sclerosis, is related to primary mediastinal large b-cell lymphoma and mediastinal gray zone lymphoma. An important gene associated with Primary Mediastinal B-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Lenalidomide and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Primary Mediastinal B-Cell Lymphoma

Diseases in the Primary Mediastinal B-Cell Lymphoma family:

Primary Mediastinal Large B-Cell Lymphoma

Diseases related to Primary Mediastinal B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 primary mediastinal large b-cell lymphoma 31.6 XPO1 BCL6
2 mediastinal gray zone lymphoma 31.0 KDM4C BCL11A
3 splenic marginal zone lymphoma 30.8 SYK BCL6 AICDA
4 lymphoma, hodgkin, classic 30.8 STAT6 SPI1 REL MIR155 KDM4C BCL6
5 marginal zone b-cell lymphoma 30.7 TNFAIP3 KDM4C BCL6
6 mediastinal malignant lymphoma 30.6 KDM4C BCL11A
7 lymphoma, mucosa-associated lymphoid type 30.3 TNFAIP3 KDM4C BCL6 AICDA
8 diffuse large b-cell lymphoma 30.2 TNFAIP3 TCL1A SYK REL MIR181A1 MIR155
9 t-cell lymphoblastic leukemia/lymphoma 30.2 XPO1 TNFAIP3 TCL1A SPI1 REL
10 follicular lymphoma 30.1 SYK MIR181A1 MIR155 BCL6 AICDA
11 b-cell lymphoma 29.9 TCL1A SYK STAT6 SPI1 REL PLCG2
12 mantle cell lymphoma 29.7 XPO1 TCL1A SYK MIR155 LYN BCL6
13 leukemia, acute lymphoblastic 29.1 SYK MIR9-1 MIR155 LYN KDM4C BLNK
14 lymphoma, non-hodgkin, familial 28.4 TCL1A SYK SPI1 MIR9-1 MIR181A1 MIR155
15 leukemia, acute myeloid 28.1 XPO1 SYK SPI1 MIR9-1 MIR181A1 MIR155
16 leukemia, chronic lymphocytic 28.1 TCL1A SYK REL PLCG2 MIR9-1 MIR181A1
17 lymphoma 10.9
18 lymphoma aids related 10.5 TCL1A BCL6
19 carbapenem allergy 10.4 SYK STAT6
20 gray zone lymphoma 10.4
21 peroxisome biogenesis disorder 11a 10.4 XPO1 REL BCL11A
22 spleen cancer 10.4 TNFAIP3 TCL1A BCL6
23 pediatric lymphoma 10.3 TCL1A BCL6
24 chromosome 2p16.1-p15 deletion syndrome 10.3 XPO1 BCL11A
25 hodgkin's lymphoma, nodular sclerosis 10.3 KDM4C BCL6
26 co-trimoxazole allergy 10.3 SYK STAT6 LYN
27 agammaglobulinemia 4, autosomal recessive 10.3 SYK BLNK
28 anaplastic large cell lymphoma 10.2
29 autoinflammatory syndrome 10.1 TNFAIP3 PLCG2
30 thymic carcinoma 10.1
31 seminoma 10.1
32 immune deficiency disease 10.1 XPO1 REL PLCG2 BCL6 AICDA
33 agammaglobulinemia, x-linked 10.0 SYK PLCG2 LYN BLNK
34 atrial standstill 1 10.0
35 non-alcoholic fatty liver disease 10.0
36 ovarian disease 10.0
37 hemopericardium 10.0
38 pericardial effusion 10.0
39 neutropenia 10.0
40 acute leukemia 10.0
41 amenorrhea 10.0
42 central nervous system lymphoma 10.0
43 t-cell acute lymphoblastic leukemia 10.0
44 acquired immunodeficiency syndrome 10.0
45 cll/sll 10.0
46 myeloid leukemia 10.0
47 fatty liver disease 10.0
48 broken heart syndrome 10.0
49 leukemia, t-cell, chronic 10.0
50 lymphosarcoma 10.0

Graphical network of the top 20 diseases related to Primary Mediastinal B-Cell Lymphoma:



Diseases related to Primary Mediastinal B-Cell Lymphoma

Symptoms & Phenotypes for Primary Mediastinal B-Cell Lymphoma

GenomeRNAi Phenotypes related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.86 SYK
2 Decreased viability GR00055-A-2 9.86 SYK
3 Decreased viability GR00221-A-1 9.86 FOXO1 SYK
4 Decreased viability GR00221-A-2 9.86 FOXO1 REL SYK
5 Decreased viability GR00221-A-3 9.86 FOXO1 LYN REL SYK
6 Decreased viability GR00221-A-4 9.86 REL
7 Decreased viability GR00249-S 9.86 SYK
8 Decreased viability GR00301-A 9.86 REL
9 Decreased viability GR00386-A-1 9.86 SYK
10 Decreased viability GR00402-S-2 9.86 SYK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.7 LYN
12 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.7 PTPN1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.7 PTPN1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.7 KDM4C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.7 STAT6
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.7 STAT6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-188 9.7 KDM4C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.7 STAT6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.7 KDM4C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.7 STAT6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.7 STAT6
22 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.7 LYN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.7 PTPN1 STAT6
24 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.7 STAT6
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.7 LYN
26 Increased shRNA abundance (Z-score > 2) GR00366-A-62 9.7 PTPN1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.7 KDM4C PTPN1 STAT6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.7 STAT6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.7 PTPN1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.7 LYN
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.7 LYN

MGI Mouse Phenotypes related to Primary Mediastinal B-Cell Lymphoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 AICDA BCL11A BCL6 BLNK FOXO1 KDM4C
2 hematopoietic system MP:0005397 10.3 AICDA BCL11A BCL6 BLNK FOXO1 KDM4C
3 homeostasis/metabolism MP:0005376 10.25 AICDA BCL11A BCL6 FOXO1 KDM4C LYN
4 immune system MP:0005387 10.25 AICDA BCL11A BCL6 BLNK FOXO1 KDM4C
5 mortality/aging MP:0010768 10.16 AICDA BCL11A BCL6 BLNK FOXO1 KDM4C
6 endocrine/exocrine gland MP:0005379 10.13 BCL11A BCL6 FOXO1 KDM4C PTPN1 SPI1
7 integument MP:0010771 10.02 AICDA BCL6 FOXO1 KDM4C LYN PLCG2
8 liver/biliary system MP:0005370 9.92 BCL6 FOXO1 LYN REL SPI1 STAT6
9 neoplasm MP:0002006 9.76 AICDA BLNK FOXO1 KDM4C PLCG2 PTPN1
10 no phenotypic analysis MP:0003012 9.5 AICDA BCL6 FOXO1 KDM4C SPI1 SYK
11 skeleton MP:0005390 9.28 FOXO1 LYN NFKBIE PLCG2 PTPN1 REL

Drugs & Therapeutics for Primary Mediastinal B-Cell Lymphoma

Drugs for Primary Mediastinal B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
2
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
4
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
5
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
6
Lenograstim Approved, Investigational Phase 2 135968-09-1
7
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
9
Melphalan Approved Phase 2 148-82-3 460612 4053
10
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Etoposide Approved Phase 2 33419-42-0 36462
13
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
14
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
15
rituximab Approved Phase 2 174722-31-7 10201696
16
leucovorin Approved Phase 2 58-05-9 6006 143
17
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
18
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
19
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
20
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
21
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
22 Angiogenesis Inhibitors Phase 1, Phase 2
23 Methylprednisolone Acetate Phase 2
24 Immunoglobulins Phase 2
25 Antibodies Phase 2
26 Antibodies, Monoclonal Phase 2
27 Etoposide phosphate Phase 2
28
Liposomal doxorubicin Phase 2 31703
29 Antineoplastic Agents, Immunological Phase 2
30 Bendamustine Hydrochloride Phase 2
31 Anti-Infective Agents Phase 1, Phase 2
32 Antiviral Agents Phase 1, Phase 2
33 Antimetabolites Phase 1, Phase 2
34 Analgesics, Non-Narcotic Phase 1, Phase 2
35 Anti-HIV Agents Phase 1, Phase 2
36 Interleukin-2 Phase 1, Phase 2
37 Anti-Retroviral Agents Phase 1, Phase 2
38 Analgesics Phase 1, Phase 2
39
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
40
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
41 Immunosuppressive Agents Phase 1
42 Immunologic Factors Phase 1
43 Antirheumatic Agents Phase 1
44 Alkylating Agents Phase 1
45
Vindesine Approved, Investigational 59917-39-4, 53643-48-4 40839
46
Ifosfamide Approved 3778-73-2 3690
47
Bleomycin Approved, Investigational 11056-06-7 5360373
48
Sargramostim Approved, Investigational Early Phase 1 83869-56-1, 123774-72-1
49
tannic acid Approved 1401-55-4
50
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT02142049 Phase 1, Phase 2 Ibrutinib;DA-EPOCH-R;Lenalidomide
2 Phase II Study of Intensive Induction (R-MegaCHOP/ESHAP)Followed By Intensive Consolidation (BEAM) In Treatment Of High-Risk Aggressive B-Cell Lymphomas Completed NCT00558220 Phase 2
3 A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL) Recruiting NCT04002622 Phase 2 TQB2450
4 Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma Recruiting NCT01859819 Phase 2 Rituximab;IT Cytarabine
5 Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas Recruiting NCT04429438 Phase 1, Phase 2
6 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma Recruiting NCT00001337 Phase 2 EPOCH
7 A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas Recruiting NCT02747732 Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
8 A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma Recruiting NCT04002947 Phase 2 DA-EPOCH;CHOP;Acalabrutinib
9 An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma Active, not recruiting NCT00924326 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin;Fludarabine;Cyclophosphamide
10 A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) Recruiting NCT02631044 Phase 1
11 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting NCT03049449 Phase 1 Cyclophosphamide;Fludarabine
12 A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting NCT04067414 Phase 1
13 T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies Active, not recruiting NCT02659943 Phase 1 Cyclophosphamide;Fludarabine
14 T Cells Expressing a Fully-Human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies Suspended NCT04160195 Phase 1 Cyclophosphamide;Fludarabine
15 A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26) Unknown status NCT00689845 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;methotrexate;prednisolone;prednisone;vincristine sulfate;vindesine
16 A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma Completed NCT00944567
17 Mediastinal Grey Zone Lymphoma: Clinico-pathological Characteristics and Outcomes of 99 Patients From the LYSA Completed NCT03037177
18 EBV-associated Diffuse Large B Cell Lymphoma NOS in Non Immunocompromised Patients : a French Retrospective Case Study Completed NCT03378947
19 Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies Completed NCT01760226 Early Phase 1 DA-EPOCH-R for DLBCL, PTLD, AND PMBCL;Methotrexate;Etoposide;Doxorubicin;Vincristine;Rituximab;Cyclophosphamide;Prednisone;G-CSF
20 Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03681535
21 IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Active, not recruiting NCT01599559

Search NIH Clinical Center for Primary Mediastinal B-Cell Lymphoma

Genetic Tests for Primary Mediastinal B-Cell Lymphoma

Anatomical Context for Primary Mediastinal B-Cell Lymphoma

MalaCards organs/tissues related to Primary Mediastinal B-Cell Lymphoma:

40
B Cells, T Cells, Bone Marrow, Bone, Thymus, Heart

Publications for Primary Mediastinal B-Cell Lymphoma

Articles related to Primary Mediastinal B-Cell Lymphoma:

(show top 50) (show all 239)
# Title Authors PMID Year
1
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma. 61
32576784 2020
2
Camrelizumab plus gemcitabine, vinorelbine and pegylated liposomal doxorubicin in relapsed/refractory primary mediastinal B-cell lymphoma: a single-arm, open-label, phase 2 trial. 61
32499235 2020
3
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. 61
32354938 2020
4
Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. 61
32496453 2020
5
High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. 61
32453838 2020
6
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. 61
32414850 2020
7
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. 61
32187361 2020
8
Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. 61
32116068 2020
9
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. 61
32030731 2020
10
Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. 61
32170099 2020
11
The immune landscape and response to immune checkpoint blockade therapy in lymphoma. 61
31790142 2020
12
An Usual Presentation of Pneumocystis jirovecii Pneumonia in a Woman Treated With Immune Checkpoint Inhibitor. 61
32097278 2020
13
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. 61
31606909 2020
14
Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases 61
32003552 2020
15
Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma. 61
32362635 2020
16
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). 61
31753925 2020
17
The impact of SOCS1 mutations in diffuse large B-cell lymphoma. 61
31407320 2019
18
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. 61
31398081 2019
19
Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. 61
31264808 2019
20
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. 61
31254155 2019
21
The Unsolved Puzzle of c-Rel in B Cell Lymphoma. 61
31277480 2019
22
CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm. 61
31777773 2019
23
Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. 61
30806751 2019
24
The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know. 61
30735060 2019
25
R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. 61
30656983 2019
26
The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. 61
30609016 2019
27
Gray-zone lymphoma. Examples of rare clinical manifestation. 61
31094484 2019
28
Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. 61
30740662 2019
29
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas. 61
30025443 2019
30
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. 61
30132131 2019
31
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. 61
30610279 2019
32
TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells. 61
30381301 2019
33
What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. 61
29528099 2019
34
What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R? 61
29532904 2019
35
HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma. 61
30448276 2019
36
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. 61
30518502 2019
37
Ten Things to Know About Primary Mediastinal B Cell Lymphoma. 61
30244100 2018
38
Utilizing multiple pathway cross-talk networks reveals hub pathways in primary mediastinal B-cell lymphoma. 61
30249889 2018
39
The unique biology and treatment of primary mediastinal B-cell lymphoma. 61
30213393 2018
40
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. 61
30310789 2018
41
How I treat primary mediastinal B-cell lymphoma. 61
29976557 2018
42
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. 61
29058502 2018
43
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. 61
29748435 2018
44
Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma. 61
30065019 2018
45
End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al. 61
30065020 2018
46
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. 61
29463854 2018
47
Superior vena cava syndrome related to mediastinal lymphoma in late pregnancy: A case report. 61
30094193 2018
48
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. 61
29720487 2018
49
MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. 61
30038718 2018
50
DA-EPOCH-R in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience. 61
30127552 2018

Variations for Primary Mediastinal B-Cell Lymphoma

Cosmic variations for Primary Mediastinal B-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143333296 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1004T>G p.L335* 6:137878449-137878449 0

Copy number variations for Primary Mediastinal B-Cell Lymphoma from CNVD:

7 (show all 32)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 16483 1 125000000 249250621 Gain Primary mediastinal b-cell lymphoma
2 37060 1 84900000 88400000 Amplification BCL10 Primary mediastinal b-cell lymphoma
3 37527 1 92000000 94700000 Amplification TGFBR3 Primary mediastinal b-cell lymphoma
4 49708 11 110400000 121200000 Gain Primary mediastinal b-cell lymphoma
5 57454 11 63400000 77100000 Gain Primary mediastinal b-cell lymphoma
6 58554 11 68400000 70400000 Loss FADD Primary mediastinal b-cell lymphoma
7 61549 12 1 35800000 Gain Primary mediastinal b-cell lymphoma
8 70078 12 58100000 67700000 Gain MDM2 Primary mediastinal b-cell lymphoma
9 77099 13 40100000 45200000 Loss Primary mediastinal b-cell lymphoma
10 88311 14 89800000 107349540 Loss Primary mediastinal b-cell lymphoma
11 89760 15 19000000 20700000 Loss Primary mediastinal b-cell lymphoma
12 106724 17 1 10700000 Loss ABR Primary mediastinal b-cell lymphoma
13 106727 17 1 10700000 Loss TUSC5 Primary mediastinal b-cell lymphoma
14 121464 18 43500000 61600000 Gain BCL2 Primary mediastinal b-cell lymphoma
15 121465 18 43500000 61600000 Gain MALT1 Primary mediastinal b-cell lymphoma
16 137935 2 154900000 169700000 Gain or amplification IL8RA Primary mediastinal b-cell lymphoma
17 137936 2 154900000 169700000 Gain or amplification IL8RB Primary mediastinal b-cell lymphoma
18 147240 2 61300000 64100000 Amplification REL Primary mediastinal b-cell lymphoma
19 147241 2 61300000 64100000 Gain or amplification BCL11A Primary mediastinal b-cell lymphoma
20 157133 21 13200000 48129895 Gain Primary mediastinal b-cell lymphoma
21 172486 3 182700000 187900000 Gain BCL6 Primary mediastinal b-cell lymphoma
22 187516 4 50400000 191154276 Loss Primary mediastinal b-cell lymphoma
23 195325 5 15000000 18400000 Amplification Primary mediastinal b-cell lymphoma
24 211275 6 32548521 32557528 Loss Primary mediastinal b-cell lymphoma
25 228595 7 77500000 98000000 Amplification CDK6 Primary mediastinal b-cell lymphoma
26 230112 7 98000000 107400000 Gain Primary mediastinal b-cell lymphoma
27 233698 8 12700000 19000000 Loss Primary mediastinal b-cell lymphoma
28 233886 8 128753680 129113499 Gain MYC Primary mediastinal b-cell lymphoma
29 244977 9 1 9000000 Amplification PDL2 Primary mediastinal b-cell lymphoma
30 244983 9 1 9000000 Gain Primary mediastinal b-cell lymphoma
31 244986 9 1 9000000 Gain or amplification JAK2 Primary mediastinal b-cell lymphoma
32 247560 9 130300000 141213431 Gain Primary mediastinal b-cell lymphoma

Expression for Primary Mediastinal B-Cell Lymphoma

Search GEO for disease gene expression data for Primary Mediastinal B-Cell Lymphoma.

Pathways for Primary Mediastinal B-Cell Lymphoma

Pathways related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 TNFAIP3 SYK STAT6 REL PTPN1 PLCG2
2
Show member pathways
13.37 SYK REL PLCG2 NFKBIE LYN FOXO1
3
Show member pathways
13.25 SYK STAT6 PTPN1 LYN FOXO1 BLNK
4
Show member pathways
13.11 SYK STAT6 PLCG2 NFKBIE LYN FOXO1
5
Show member pathways
12.65 XPO1 TNFAIP3 SYK PLCG2 NFKBIE LYN
6
Show member pathways
12.55 SYK REL PLCG2 NFKBIE LYN FOXO1
7
Show member pathways
12.53 SYK REL PLCG2 NFKBIE LYN BLNK
8 12.44 PLCG2 MIR9-1 MIR181A1 MIR155
9
Show member pathways
12.39 REL PTPN1 PLCG2 FOXO1
10
Show member pathways
12.33 SYK SPI1 NFKBIE LYN
11
Show member pathways
12.33 SYK REL PLCG2 NFKBIE LYN BLNK
12
Show member pathways
12.29 REL PLCG2 NFKBIE FOXO1
13 12.17 SPI1 REL FOXO1 BCL6
14
Show member pathways
12.13 SYK REL PLCG2 NFKBIE LYN FOXO1
15
Show member pathways
12.09 SYK REL PLCG2 NFKBIE BLNK
16
Show member pathways
11.96 SYK PLCG2 LYN BLNK
17
Show member pathways
11.95 SYK REL PLCG2 NFKBIE LYN FOXO1
18 11.94 SYK SPI1 PLCG2 BLNK
19 11.89 STAT6 FOXO1 BCL6
20
Show member pathways
11.88 STAT6 REL NFKBIE
21 11.88 TNFAIP3 SYK STAT6 SPI1 REL PLCG2
22
Show member pathways
11.85 SYK PLCG2 LYN
23
Show member pathways
11.85 SYK PLCG2 LYN BLNK
24 11.82 TNFAIP3 SYK PLCG2 LYN
25 11.76 SYK PLCG2 LYN
26 11.74 TNFAIP3 SYK PLCG2 LYN BLNK
27 11.53 STAT6 SPI1 BCL6 AICDA
28
Show member pathways
11.5 SYK PLCG2 LYN
29 11.42 XPO1 FOXO1 BCL6
30
Show member pathways
11.11 SYK REL NFKBIE
31 10.91 SYK LYN BLNK
32 10.87 STAT6 SPI1
33 10.77 SYK REL

GO Terms for Primary Mediastinal B-Cell Lymphoma

Cellular components related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.1 XPO1 TNFAIP3 TCL1A SYK STAT6 REL
2 cytoplasm GO:0005737 10.1 XPO1 TNFAIP3 TCL1A SYK STAT6 REL
3 nucleus GO:0005634 10 XPO1 TNFAIP3 TCL1A SYK STAT6 SPI1
4 protein-containing complex GO:0032991 9.1 XPO1 TCL1A SYK PTPN1 LYN AICDA
5 mitochondrial crista GO:0030061 8.96 PTPN1 LYN

Biological processes related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.91 TNFAIP3 REL LYN BLNK BCL6
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.8 XPO1 STAT6 SPI1 REL FOXO1 BCL6
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.77 SYK PLCG2 LYN
4 platelet activation GO:0030168 9.76 SYK PLCG2 LYN
5 miRNA mediated inhibition of translation GO:0035278 9.75 MIR9-1 MIR181A1 MIR155
6 cellular response to hydrogen peroxide GO:0070301 9.71 TNFAIP3 STAT6 FOXO1
7 positive regulation of type I interferon production GO:0032481 9.63 SYK STAT6 PLCG2
8 B cell receptor signaling pathway GO:0050853 9.62 SYK PLCG2 LYN BLNK
9 negative regulation of innate immune response GO:0045824 9.61 TNFAIP3 MIR155
10 negative regulation of interleukin-1 beta production GO:0032691 9.61 TNFAIP3 MIR181A1
11 negative regulation of JAK-STAT cascade GO:0046426 9.59 MIR9-1 MIR155
12 dendritic cell differentiation GO:0097028 9.57 MIR155 LYN
13 negative regulation of toll-like receptor 4 signaling pathway GO:0034144 9.56 TNFAIP3 LYN
14 positive regulation of cellular component movement GO:0051272 9.55 LYN BCL6
15 negative regulation of type 2 immune response GO:0002829 9.52 STAT6 BCL6
16 regulation of platelet aggregation GO:0090330 9.49 SYK LYN
17 regulation of erythrocyte differentiation GO:0045646 9.48 SPI1 LYN
18 B cell differentiation GO:0030183 9.46 PLCG2 BLNK BCL6 AICDA
19 positive regulation of dendritic cell apoptotic process GO:2000670 9.43 MIR155 LYN
20 negative regulation of toll-like receptor 2 signaling pathway GO:0034136 9.4 TNFAIP3 LYN
21 regulation of germinal center formation GO:0002634 9.37 TNFAIP3 BCL6
22 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.13 STAT6 PTPN1 LYN
23 regulation of cell proliferation GO:0042127 9.1 SYK STAT6 MIR155 LYN FOXO1 BCL6

Molecular functions related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.63 STAT6 SPI1 REL FOXO1 BCL6 BCL11A
2 DNA-binding transcription repressor activity, RNA polymerase II-specific GO:0001227 9.26 SPI1 FOXO1 BCL6 BCL11A
3 sequence-specific DNA binding GO:0043565 9.1 STAT6 SPI1 REL FOXO1 BCL6 BCL11A

Sources for Primary Mediastinal B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....